# Common Bone Drugs May Also Slow Aging in the Heart and Liver

*Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures.*

- **Evidence Level**: Moderate
- **Publication Types**: Journal Article
- **Journal**: Signal transduction and targeted therapy
- **Sample Size**: Aged mice, human cells, and plasma from postmenopausal women in a trial
- **Authors**: Lu J, Rao SR, Knowles H, Zhan H, Gamez B, Qin M, Platt E, Frost LR, Allen TJ, Marshall G, Huber KVM, Bauer LG, Vendrell I, O'Brien DP, Kessler B, Horne A, Reid IR, Bountra C, Kirkland JL, Khosla S, Ebetino FH, Roldan E, Russell RGG, Edwards JR
- **Published**: 2026-07-15
- **Topics**: bisphosphonates, senescence, heart health
- **DOI**: https://doi.org/10.1038/s41392-026-02799-x
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/42448670/

## Summary

Bisphosphonates are old, widely used drugs for bone loss like osteoporosis. This study found they may do far more than protect bones. In aged mice and in blood from women in a trial, these drugs shifted aging markers toward a younger pattern in the heart, liver, and gut. They also protected human heart cells from becoming worn out and damaged.

## Practical Takeaway

This study suggests bone drugs may have wider anti-aging effects, but that needs dedicated human trials.

---

_Canonical: https://longevity-china.com/en/research/common-bone-drugs-may-also-slow-aging-in-the-heart-and-liver · Part of Longevity Cities · Updated 2026-07-15_